There was no difference in the frequency of CD19+ cells in SSc-ILD patients who were being treated versus those not on therapy at the time of enrollment (7.9 ± 1.8% vs. 7.8 ± 1.8%, p = 0.33). This evidence concerns the gene CD19 and systemic sclerosis.